Please assess the completion status of the following clinical trial:

Trial Title: Bintrafusp Alfa Monotherapy in Platinum-Experienced Cervical Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participants who had advanced unresectable and/or metastatic cervical cancer (squamous cell carcinoma, adenocarcinoma, adenosquamous cell carcinoma) with disease progression during or after the prior platinum-containing chemotherapy:~  1. The prior platinum-containing chemotherapy may be a systemic treatment for advanced unresectable, recurrent, persistent or metastatic disease or treatment in the adjuvant or neo-adjuvant setting with disease progression or recurrence within 6 months of completion of platinum-containing chemotherapy~ 2. Participants who previously only received platinum as a radiosensitizer are not eligible~ 3. Participants must be naïve to checkpoint inhibitors~* Participants who had measurable disease~* Participants who provide a tumor tissue sample, either from archival tissue or newly obtained core or excisional biopsy. If the participant received local therapy (For example: radiation therapy or chemoradiotherapy) after the archival tissue was taken, a new biopsy was required~* Participants who had Eastern Cooperative Oncology Group (ECOG) PS of 0 to 1~* Life expectancy greater than or equals to (\>=) 12 weeks as judged by the Investigator~* Adequate hematological, hepatic and renal function as defined in the protocol~* Participants with known Human Immunodeficiency Virus (HIV) infections were in general eligible if the following criteria are met:~  1. Clinically indicated participants must be stable on antiretroviral therapy (ART) for at least 4 weeks and agree to adhere to ART~ 2. had no evidence of documented multi-drug resistance that would prevent effective ART~ 3. had an HIV viral load of \< 400 copies per milliliter (/mL) at Screening~ 4. had CD4+ T-cell (CD4+) counts \>= 350 cells/microliter~ 5. For participants with a history of an Acquired immunodeficiency syndrome (AIDS)-defining opportunistic infection within the last 12 months, participants may be eligible only after consultation and agreement with the study Medical Monitor~ 6. If prophylactic antimicrobial drugs were indicated, participants would still be considered eligible upon agreement with the study Medical Monitor~* Participants with hepatitis B virus (HBV) and/or hepatitis C virus (HCV) infections were in general eligible if the following criteria are met:~  1. HBV viral load below the limit of quantification. If medically indicated, participants infected with HBV must be treated and on a stable dose of antivirals at study entry and with planned monitoring and management according to appropriate labeling guidance~ 2. Participants with a history of HCV infection should have completed curative antiviral treatment and require HCV viral load below the limit of quantification~ 3. Participants on concurrent HCV treatment should have HCV below the limit of quantification~* Other protocol defined inclusion criteria could apply~Exclusion Criteria:~* Participants with active central nervous system (CNS) metastases causing clinical symptoms or require therapeutic intervention are excluded. Participants with a history of treated CNS metastases (by surgery or radiation therapy) are not eligible unless they have fully recovered from treatment, demonstrated no progression for at least 4 weeks, and are not using steroids for at least 7 days prior to the start of study treatment~* Participants with interstitial lung disease or has had a history of pneumonitis that has required oral or intravenous (IV) steroids~* Participants with significant acute or chronic infections~* Participants with active autoimmune disease that might deteriorate when receiving an immunostimulatory agent~* Participants with clinically significant cardiovascular/cerebrovascular disease including: cerebral vascular accident/stroke, myocardial infarction, unstable angina, congestive heart failure, or serious cardiac arrhythmia~* Other protocol defined exclusion criteria could apply

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bintrafusp alfa (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete